|
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) |
|
Amylyx Pharmaceuticals Inc
AMLX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Amylyx Pharmaceuticals Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1327
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.44 %
Amylyx Pharmaceuticals Inc net loss decreased from $-119 millions, to $-36 millions in first quarter of 2025,
• More on AMLX's Growth
|
|
Amylyx Pharmaceuticals Inc realized a net loss in trailing twelve months.
Amylyx Pharmaceuticals Inc realized cash reduction of $ -1.28 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.48.
• More on AMLX's Valuation
|
|
|
|
|
Amylyx Pharmaceuticals Inc realized net loss in trailing twelve months.
Amylyx Pharmaceuticals Inc realized cash outflow of $ -1.28per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.48.
Amylyx Pharmaceuticals Inc Price to Book Ratio is at 3.08 lower than Industry Avg. of 35.08. and higher than S&P 500 Avg. of 0.01
• More on AMLX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com